<DOC>
	<DOCNO>NCT00004059</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . UCN-01 may increase effectiveness chemotherapy drug make tumor cell sensitive drug . PURPOSE : Phase I trial study effectiveness fluorouracil plus UCN-01 treating patient advance refractory solid tumor .</brief_summary>
	<brief_title>Fluorouracil Plus UCN-01 Treating Patients With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose , dose limit toxicity , toxicity profile fluorouracil UCN-01 patient advanced refractory solid tumor . - Assess clinical pharmacokinetics regimen correlate observed toxicity patient . - Obtain preliminary data therapeutic activity regimen patient . OUTLINE : This dose escalation study fluorouracil . Patients receive fluorouracil IV 24 hour day 1 , 8 , 15 , 22 . Patients receive initial dose UCN-01 IV 72 hour begin day 2 course 1 maintenance UCN-01 IV 36 hour begin day 2 subsequent course . Treatment repeat every 4 week least 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos fluorouracil maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 6-48 patient accrue study within approximately 14 month .</detailed_description>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor refractory standard therapy standard therapy exist Measurable evaluable disease No CNS metastasis primary CNS malignancy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC great 3,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No history coronary artery disease document prior myocardial infarction , angiography , coronaryartery bypass graft No cardiac arrhythmias congestive heart failure within past 6 month Stable atrial fibrillation standard treatment allow discretion investigator Pulmonary : DLCO least 60 % predict Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study No active serious uncontrolled infection HIV negative No diabetes No medical condition would preclude study PRIOR CONCURRENT THERAPY : See Disease Characteristics Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior fluorouracil allow Endocrine therapy : Not specify Radiotherapy : No prior mediastinal radiotherapy At least 4 week since prior radiotherapy recover Surgery : Not specify Other : No concurrent anticonvulsant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>